WNT7B and breast carcinoma: Finally, analysis of 166 estrogen receptor (ER) positive human breast cancer cases showed enhanced levels of WNT7B in breast cancers with loss-of-function mutations in the upstream JNK pathway components MAP2K4 and MAP3K1 (Figure 7d).